{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T04:44:31Z","timestamp":1769316271537,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2006,5,8]],"date-time":"2006-05-08T00:00:00Z","timestamp":1147046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2006,5,8]],"date-time":"2006-05-08T00:00:00Z","timestamp":1147046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1111\/j.1365-2133.2006.07316.x","type":"journal-article","created":{"date-parts":[[2006,5,8]],"date-time":"2006-05-08T16:58:52Z","timestamp":1147107532000},"page":"160-169","source":"Crossref","is-referenced-by-count":46,"title":["Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study"],"prefix":"10.1093","volume":"155","author":[{"given":"C.H.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.J.","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Wain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.N.W.N.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,5,8]]},"reference":[{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4400","article-title":"A systematic review of treatments for severe psoriasis","volume":"4","author":"Griffiths","year":"2000","journal-title":"Health Technol Assess"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.0022-202X.2003.09101.x","article-title":"Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis","volume":"122","author":"Sampogna","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1087-0024.2003.09102.x","article-title":"Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction","volume":"9","author":"Stern","year":"2004","journal-title":"J Invest Dermatol Symp Proc"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1067\/mjd.2001.114592","article-title":"Physical and psychologic measures are necessary to assess overall psoriasis severity","volume":"45","author":"Kirby","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2133.2006.07316.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"s57","DOI":"10.1016\/S0190-9622(03)01136-8","article-title":"Quality of life issues in psoriasis","volume":"49","author":"Choi","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis: consensus conference","volume":"38","author":"Roenigk","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1365-2133.2004.06105.x","article-title":"Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab","volume":"151","author":"Chew","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1067\/mjd.2003.307","article-title":"Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis","volume":"48","author":"Gottlieb","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/039463200401700317","article-title":"Infliximab monotherapy for refractory psoriasis: preliminary results","volume":"17","author":"Cassano","year":"2004","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJM200202213460815","article-title":"Tuberculosis and treatment with infliximab","volume":"346","author":"Lim","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1093\/rheumatology\/kei103","article-title":"British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF\u03b1 treatments","volume":"44","author":"Ledingham","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/424455","article-title":"Granulomatous infections due to tumor necrosis factor blockade: correction","volume":"39","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archderm.139.11.1425","article-title":"Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom","volume":"139","author":"Gelfand","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1523-1747.2003.12350.x","article-title":"The increased risk of skin cancer is persistent after discontinuation of psoralen\u2003+\u2003ultraviolet A: a cohort study","volume":"121","author":"Nijsten","year":"2003","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1046\/j.0022-202x.2001.01520.x","article-title":"Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden","volume":"117","author":"Boffetta","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2006.07316.x-BIB27|cit27","first-page":"778","article-title":"The risk of malignancy associated with psoriasis","volume":"137","author":"Margolis","year":"2001","journal-title":"Arch Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2006.07316.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2006.07316.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2006.07316.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:17:23Z","timestamp":1676384243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/155\/1\/160\/6637144"}},"subtitle":["Infliximab for severe, treatment-resistant psoriasis"],"short-title":[],"issued":{"date-parts":[[2006,5,8]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07316.x","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5,8]]}}}